Developing innovative and sustainable wound care technology, with marine ingredients from the coast of Norway
Regenics AS is a private Norwegian biotechnology company based in Oslo. The company develops a range of wound care products, with a current pipeline of two medical devices and one novel drug.
Target diagnoses and applications include burns, diabetic wounds, chronic wounds, and enzymatic wound debridement. One of our major innovations, HTX™, is sourced and purified from unfertilized salmon roe.
Target diagnoses and applications include burns, diabetic wounds, chronic wounds, and enzymatic wound debridement. One of our major innovations, HTX™, is sourced and purified from unfertilized salmon roe.
With the unique qualities of unfertilized salmon roe, trout roe enzymes and other natural, marine ingredients, we aim to redefine current standards of care in wound management. We reduce waste in the aquaculture industry, and sustainability is at the core of everything we do.
ABOUT REGENICS
Collex® is a unique, 3D printed, advanced wound dressing containing HTX™ from salmon roe. Collex® is intended to aid healing of partial thickness burns and chronic wounds, and is currently in pre-clinical development.
Vernex® is an HTX™-based hydrogel wound spray, intended for treatment of partial thickness burns and chronic wounds. Vernex® is currently in pre-clinical development.
WoundClear™ is a novel investigational drug derived from trout LCE, intended for enzymatic wound debridement. WoundClear™ is currently in the discovery stage.
Our products
Pipeline
Feasibility
Pre-Clinical
Pivotal
Discovery
REG212
Wound healing
HTX from salmon roe• Advanced wound dressing• Medical device
Feasibility
Pre-Clinical
Pivotal
Discovery
REG320
Wound healing
HTX from salmon roe • Hydrogel wound spray• Medical device
Phase 1
Discovery
Phase 2
Phase 3
Pre-Clinical
REG410
Wound healing
LCE from trout • Enzymatic debridement• Novel drug
News
Team
-
- Geir UtigardHead of CMC
- Anniken LiljebergQA Manager
- Karl Rasmus BrynChief Medical Officer
Board
- Jan AlfheimChairman of the Board
- Runhild GammelsæterBoard Member
- Tore Heldrup RasmussenBoard member
- Harald NordalBoard Member
- Brynjolfur EyjolfssonBoard member
- Beat MoserBoard Member
Chief Executive Officer
Karl Rasmus Bryn
Karl R. Bryn is the Chief Medical Officer of Regenics AS
Chief Executive Officer
Karin Gilljam
Karin Gilljam is the Chief Executive Officer of Regenics AS, previously having served as the company's Chief Scientific Officer. Karin has a PhD from the University of Oslo, and came to Regenics from a Postdoc position at the UiO Department of Molecular Medicine.
Karin has an extensive academic background in biochemistry, molecular medicine, immunology and oncology. Previously she has held a Postdoc position at NTNU Trondheim, Department of Cancer Research and Molecular Medicine.
Karin has an extensive academic background in biochemistry, molecular medicine, immunology and oncology. Previously she has held a Postdoc position at NTNU Trondheim, Department of Cancer Research and Molecular Medicine.
Partners
